Lipidomic markers for Hepatitis C and related conditions, treat hepatic fibrosis and hepatocellular carcinoma. An agent administered to such subject may be an iminosugar, which may be effective against hepatitis C. Such iminosugar may be, for example, one of N- substituted deoxynojrimycins and pharmaceutically acceptable salts thereof, N-substituted deoxygalactonojirimycins and pharmaceutically acceptable salts thereof and N-substituted Me- deoxygalactonojirimycins and pharmaceutically acceptable salts thereof. A method of assessing a Hepatitis C infection or a condition caused by or associated with said infection. This method comprises: obtaining a biological sample from a subject in need thereof determining a level of at least one Hepatitis C lipidomic biomarker in said biological sample and comparing said level of with a control level of said Hepatitis C lipidomic biomarker to assess the Hepatitis C infection or the condition caused by or associated with said infection in the subject.La présente invention concerne de nouveaux marqueurs lipidomiques pour lhépatite C et des états associés, tels la fibrose hépatique et un carcinome hépatocellulaire.
